Princeton Capital Advisors (“PCA”) is a global independent advisory firm that provides innovative, unconflicted and fact-based strategic advice to a diverse client base on many of their most important financial, investment and transactional decisions. We are the transaction advisory affiliate of the Albright Stonebridge Group, the leading international strategic consulting firm at the intersection of the public and private sectors.

We assist our clients in achieving their strategic goals by offering comprehensive, globally integrated advisory services that reflects both deep industry knowledge and experience and top-tier financial and transaction expertise.

Zaki Hosny

Zaki Hosny

Vice Chairman

Mr. Hosny has spent over three decades in the international pharmaceutical industry and uses his experience to help clients achieve their strategic goals in overseas markets. Immediately prior to founding Princeton Capital Advisors, Mr. Hosny was Chief Executive Officer of Motif BioSciences Inc, a private genomics and drug discovery firm.

Mr. Hosny has spent over three decades in the international pharmaceutical industry and uses his experience to help clients achieve their strategic goals in overseas markets. Immediately prior to founding Princeton Capital Advisors, Mr. Hosny was Chief Executive Officer of Motif BioSciences Inc, a private genomics and drug discovery firm.

Previously, Mr. Hosny spent most of his career at Merck & Co in marketing & general management positions around the globe. Regional management positions included responsibility for the company’s business in its Mid Europe Region and Scandinavia. In these positions, he gained a wealth of experience in diverse market access, pricing and reimbursement, regulatory, and government relations issues.

Mr. Hosny also held senior marketing roles with worldwide responsibility for cardiovascular and other franchises, and was closely involved in the clinical development program for some of the company’s major products.

Mr. Hosny is also a Senior Advisor to the Health and Life Sciences practice at the Albright Stonebridge Group.

Mr. Hosny is a graduate of Cambridge University with a M.A. is History and Law. He is fluent in French. Mr. Hosny is based in Princeton, NJ.

Nigel Thompson

Nigel Thompson

Vice Chairman

Mr. Thompson has 30+ years of experience in international pharmaceutical markets. He was an Executive Director of Economic and Development Strategy at Merck & Co. and held various senior roles across the organization. During his tenure at Merck, he played an active role in designing and implementing strategies to accelerate and protect market access in European and emerging markets.

Mr. Thompson has 30+ years of experience in international pharmaceutical markets. He was an Executive Director of Economic and Development Strategy at Merck & Co. and held various senior roles across the organization. During his tenure at Merck, he played an active role in designing and implementing strategies to accelerate and protect market access in European and emerging markets. Mr. Thompson has substantial experience in economic strategy, pricing and reimbursement, government relations, and business development.

Mr. Thompson is also a Senior Advisor to the Albright Stonebridge Group on Health and Life Sciences matters, and has also been Pharmaceutical Advisor to the World Bank on pharmaceutical issues in emerging markets and developed dialogues between pharmaceutical companies and the World Bank.

He is also a British Chartered Accountant. Mr. Thompson is fluent in French. He is based in New York City.

Murali

Murali Parthasarathy

Managing Director

Murali has more than 25 years of experience in consulting, business development, marketing, sales management, distribution and category Management in a number of well-established global players, including Merck, Medco (now Express Scripts), Dun & Bradstreet and SC Johnson Wax.

Murali has more than 25 years of experience in consulting, business development, marketing, sales management, distribution and category Management in a number of well-established global players, including Merck, Medco (now Express Scripts), Dun & Bradstreet and SC Johnson Wax.

His work at Merck and Medco ranged from strategy development, strategic planning, and implementation of international growth initiatives, For the past 10 years, Murali has advised a number of clients on identifying pharmaceutical assets available for sale or strategic placement worldwide.

Murali has an MBA in finance and marketing from the Booth School at the University of Chicago and an MS in Statistics from Oklahoma State University.

Abhay Pande

Abhay Pande

Managing Director

Abhay has over 28 years’ senior experience in investment banking, strategy consulting, and private equity. Alongside is work at Princeton Capital Advisors, Abhay is a partner at Linnean Capital Management, an US-based quantitative asset management firm, and chairman of Ironmont Hydro, Ltd, a Singapore-based investment holding company, and is a commissioner at PT Arkora Hydro.

Abhay has over 28 years’ senior experience in investment banking, strategy consulting, and private equity. Alongside is work at Princeton Capital Advisors, Abhay is a partner at Linnean Capital Management, an US-based quantitative asset management firm, and chairman of Ironmont Hydro, Ltd, a Singapore-based investment holding company, and is a commissioner at PT Arkora Hydro.

Previously, Abhay was Managing Director at American Capital, a publicly listed private equity firm. While there, he established and oversaw the firm’s operations in Asia, and was a member of the Energy and Infrastructure fund’s investment committee.

He spent 16 years at Citigroup’s investment banking department (formerly Salomon Smith Barney) where he was a Managing Director, co-head of Asian Energy investment banking, and Head of Southeast Asia Industrials. During this time at Salomon Smith Barney and Citigroup, he oversaw, originated, led or executed several hundred transactions, including over $35 billion of loans, bond and equity transactions and over $32 billion in mergers & acquisition transactions. Prior to joining Salomon Smith Barney in 1998, Mr. Pande was a Principal at global management consulting firm A.T. Kearney Inc., where he worked on strategy and mergers & acquisition assignments.

Mr. Pande has an AB in quantitative economics from Dartmouth College, and an MBA with high honors in finance and strategy from the Booth School at the University of Chicago, where he was a Wallman Scholar.  He is based in the New York City area.

Branimir Brankov

Senior Advisor

Branimir Brankov is a Pharma industry leader, a Medical Doctor with 30+ years of Pharmaceutical industry experience. Experience includes establishing and turning around business in multiple therapies (Oncology, Vaccines, CNS, biosimilars, etc.).

Branimir Brankov is a Pharma industry leader, a Medical Doctor with 30+ years of Pharmaceutical industry experience.  Experience includes establishing and turning around business in multiple therapies (Oncology, Vaccines, CNS, biosimilars, etc.).  Branimir earned his MD and PhD degrees at the Medical Academy in Sofia Bulgaria and an MBA from Rutgers University.

Prior to joining PCA, Branimir was VP, Business and Corporate Development and Head of BD for Ex-US Markets.  Most recently, Branimir was Regional Managing Director for 11 countries in Europe.

Nidal

Nidal Fakhoury

Senior Advisor

Nidal is well-positioned to work alongside and advise our international and local clients, harnessing our firmly-established connections with stakeholders in the region as well as our experience in public policy and government affairs, market entry and growth strategy, collaboration and partnerships, business transformation and transaction advisory.

Nidal Fakhoury is based in Dubai and provides local and international healthcare companies with a platform to support strong and sustainable growth in the MENA region.

Nidal is part of a team with extensive cross-sector MENA experience, having held executive and business management roles in leading pharmaceutical organizations, leadership roles in industry associations, and advisory roles across an array of sectors. Nidal is well-positioned to work alongside and advise our international and local clients, harnessing our firmly-established connections with stakeholders in the region as well as our experience in public policy and government affairs, market entry and growth strategy, collaboration and partnerships, business transformation and transaction advisory.

Susan Finston

Senior Advisor

Susan Kling Finston, JD/MPP is a key opinion leader (KOL) on innovation and the value of intellectual property (IP) for assimilation of new technologies and creation of social and economic benefit, provides integrated marketing / business development strategies for individual companies ranging from Fortune-100 to MSMEs, including technology transfer and product licensing, bilateral / multilateral negotiation and policy advocacy for innovative organizations.

With 25+ years of work experience at top echelons of corporations and government, Susan’s milestones include transactions in excess of $100M, market access and strategic partnering agreements for Fortune-100 companies, and thought leadership in support of intellectual property and trade reforms in India, Saudi Arabia, Egypt, and other key emerging markets. She also has completed successful engagements in multilateral negotiations including the TransPacific Partnership (TPP), Convention on Biological Diversity (CBD), World Health Organization (WHO), World Intellectual Property Organization (WIPO), and World Trade Organization (WTO). She served as a cleared advisor (Secret level) to the Commerce Department and the U.S. Trade Representative (IPR, Tariff/Trade Facilitation).
In 2005 Susan founded Finston Consulting LLC to to support innovative companies ranging from Fortune 100 to start-ups, governments, and NGOs. Previous experience includes 5 years at the Pharmaceutical Research and Manufacturers of America (PhRMA). As PhRMA Associate Vice President for Intellectual Property, Middle East/Africa and South Asian Affairs, she led the international campaign for patent law reform in India. From 1988 to 1999, she served in the U.S. Foreign Service (State Department). Susan is a member of the Illinois State Bar and the U.S. Supreme Court Bar, and received a Juris Doctor and Masters of Public Policy from the University of Michigan (1986).
Juan Carlos Hartasanchez

Juan Carlos Hartasanchez

Director, Head of EMEA and Latin America

Juan Carlos Hartasánchez is Director and Head of EMEA and LatAm at Princeton Capital Advisors. He has over a decade of experience on emerging-market entry and growth strategies, cross-border transaction advisory, and dispute resolution.

Juan Carlos Hartasánchez is Director and Head of EMEA and LatAm at Princeton Capital Advisors. He has over a decade of experience on emerging-market entry and growth strategies, cross-border transaction advisory, and dispute resolution. Alongside his work at Princeton Capital Advisors, Juan Carlos is a Senior Advisor at the Albright Stonebridge Group (ASG), where he previously was Vice President and advised companies on regional growth strategies by identifying business opportunities, assessing the regulatory environment, evaluating risks, and establishing strategic partnerships. He also participated in the firm’s management and new client development efforts.

Previously, Juan Carlos was Manager of Business Development for Rev Worldwide, a fintech company, and Business Analyst at MPower Labs, an R&D incubator and business accelerator where he evaluated investment opportunities. Earlier in his career, Juan Carlos worked at a boutique investment bank in Mexico City, at the Central Bank of Mexico, and consulted for the Ministry of Finance of Mexico City.

Juan Carlos has appeared on Bloomberg and is regularly quoted on Latin America economic and political issues in outlets including CNBC, Mexico Daily News, The New York Times, and POLITICO.

He earned his M.B.A. at Harvard Business School, and his B.S. in Economics from the Instituto Tecnológico Autonómo de México (ITAM), with a specialization in Finance. Juan Carlos has also completed certification courses on advanced valuation at NYU Stern School of Business.

Juan Carlos speaks fluent English and Spanish, and is proficient in French. He is based in Madrid, Spain.

Arthur Hiller

Senior Advisor

Arthur Hiller is a Boston-based biopharma executive. Over the last decade, he has been CEO of two early stage companies in the areas of drug discovery and cardiovascular medical devices. He currently provides consulting and business advisory support, and serves in part-time senior executive operating and mentoring roles for a wide range of start-up and early stage companies in the Boston area. His career spans more than 35 years of experience across a wide range of functional areas and sectors of the life sciences and healthcare technology industry, where he has held executive positions in general management, marketing, sales, sales management, and business development at Millennium Pharmaceuticals, Inc., Merck and Co, and two other large, multinational pharmaceutical companies.

Arthur has extensive experience across a wide range of functional areas and segments of the life sciences industry. He has been CEO of two early-stage life sciences companies in the medical device and drug discovery areas. His current engagements include roles as CEO of Amasa Therapeutics, an oncology company developing engineered cell therapies to treat glioblastoma and solid tumors, and CBO of Nuritas, Ltd. an artificial intelligence based, peptide-focused drug discovery company. They follow recent leadership and advisory roles with Antyllus Therapeutics, Smith Therapeutics, and Gro Biosciences, companies developing cardiovascular therapeutics, cell-based therapeutics for neurodegenerative disease, and novel therapeutics based on computational protein design and synthetic biology, respectively. Through his consulting company, Hiller Life Sciences Strategies, LLC, he also provides commercial strategy consulting, including recent engagements with venture-backed companies focused on obesity, the microbiome, and melanoma, major multinational pharma companies launching new products in women’s health and rare diseases, an early stage diagnostic company, and a medical device company with novel technology for otolaryngology applications.

Previously, as CEO of Cambridge-based SciFluor Life Sciences, LLC, a private-equity backed company utilizing fluorine chemistry to improve characteristics of drug molecules, Arthur negotiated an expanded license agreement with Harvard University, and recruited an elite management and chemistry team that filed IP and began preclinical development of 13 new compounds for use in treating CNS diseases, infectious disease, and inflammatory and ophthalmic conditions. In a prior CEO role at Heartscape Technologies, he successfully launched a novel electrocardiogram (ECG) technology clinically proven to identify heart attacks not visible to the 12-lead ECG, raised $22M in B-round funding, and built a high-performing, successful team. He sold Heartscape to the medical device division of a Fortune 1000 company in early 2010.

Arthur has also held executive positions in general management, marketing, sales, sales management, and business development at Millennium Pharmaceuticals, Inc., Merck and Co, and two other large, multinational pharmaceutical companies. At Millennium, he was Senior Vice President, responsible for the cardiovascular business unit, including sales and marketing of INTEGRILIN®, new product marketing for the Millennium pipeline, and customer segment and channel management. He joined Millennium in 2001 as General Manager, Inflammation, and was subsequently named General Manager, Cardiovascular in 2002, and Senior Vice President, Global Strategic Marketing in 2003.

While at Merck as Vice President, Worldwide Human Health Marketing, Hospital Products, Arthur was involved in the global launch of AGGRASTAT® (tirofiban HCI), global marketing leadership of PRIMAXIN® (Imipenem) and pre-launch development of INVANZ® (ertapenem sodium) and CANCIDAS® (caspofungin acetate). He was also responsible for Merck managed care initiatives outside the United States, and served as Senior Vice President, Business Development for Merck-Medco Managed Care, where he focused his efforts on the conceptualization and execution of numerous alliances with pharmaceutical manufacturers to support and expand Merck-Medco disease management programs.

Arthur holds a Bachelor’s Degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University, serves as Lecturer and faculty member of the Healthcare Ventures class and the IMPACT Innovation program at MIT, and in Advisory Board, fundraising, and business development capacities for a wide range of start-up and early stage companies in the Boston area.

Ken Hyatt

Ken Hyatt

Senior Advisor

Ken Hyatt is Senior Advisor at Princeton Capital Advisors, where he advises clients of the firm on complex international transactions, and investment matters in international markets. Prior to joining PCA, Mr. Hyatt served in the U.S. Department of Commerce as the Acting Under Secretary and Deputy Under Secretary for International Trade. Previously, Mr. Hyatt formed CMPartners, a negotiation consulting firm, where he was founder and partner, and was a management consultant with Bain & Company.

Ken Hyatt is Senior Advisor at Princeton Capital Advisors, where he advises clients of the firm on complex international transactions, and investment matters in international markets.

Prior to joining PCA, Mr. Hyatt served in the U.S. Department of Commerce as the Acting Under Secretary and Deputy Under Secretary for International Trade. He oversaw the strategy and operations of the International Trade Administration (ITA) with an annual budget of approximately $500 million and more than 2,200 employees worldwide. He led ITA which contributes to the development of U.S. trade policy; identifies and resolves market access and compliance issues; promotes U.S. competitiveness and the strength of U.S. companies in the global economy; administers U.S. trade laws; and undertakes a range of trade and investment promotion and trade advocacy efforts. In this role, he worked with a wide range of U.S. companies helping them achieve their international objectives and with foreign governments on the development and implementation of trade and investment policies. He also co-led the creation of SelectUSA, the U.S. government’s investment attraction agency, led the U.S. government’s support for BrandUSA, the U.S. national tourism promotion organization, and co-led the development of the U.S. National Travel and Tourism Strategy.

Previously, Mr. Hyatt formed CMPartners, a negotiation consulting firm, where he was founder and partner. Earlier in his career, Mr. Hyatt was a Principal at Conflict Management Inc. and a management consultant with Bain & Company in its Boston, London, and Munich offices. At Bain, he led teams of consultants analyzing and implementing a variety of strategic and organizational projects at leading American and European multinational corporations, focusing on strategy development, mergers and acquisitions, sales and marketing strategy, and training.

Mr. Hyatt also has been an Associate at the Harvard Negotiation Project where he taught seminars for business executives, law, and other graduate students.

Mr. Hyatt received a B.A. from Yale College, a J.D. from Harvard Law School, and was a Fulbright/West German Exchange Service Scholar. He speaks German.

He is based in Washington, D.C.

Dr. Alexander Kraus

Senior Advisor

Dr. Alexander Kraus is an accomplished international executive with 20+ years of experience in the pharma industry. He held positions as the former Head of Pharmacokinetics at Grünenthal GmbH, GM/Vice President TRF Business at Grünenthal USA, Inc., and Head Search&Evaluation at Aquestive Therapeutics. Dr. Kraus is a proprietor consultant at AK Pharma Consulting since 2017.

Dr. Alexander Kraus is an accomplished international pharmaceutical executive with more than 20 years of experience in branded pharmaceutical industry. Dr. Kraus provides broad experience in R&D, business and portfolio development, strategic communications for products and delivery technologies in pain/CNS, prescription drug abuse prevention, emergency treatment, and beyond.

Dr. Kraus started his career at German pain specialty company Grünenthal GmbH in 1999. During his time as Head of Pharmacokinetics at Grünenthal between 2001 and 2009 he was part of the preclinical and clinical stage-gate committees for development candidate selection and contributed significantly to the development and European market approval of various products like buprenorphine transdermal patch (TRANSTEC®), lidocaine hydrogel patch (VERSATIS®), and tapentadol (PALEXIA®).

After relocation to the US in 2009 Dr. Kraus was responsible for marketing and partnering of Grünenthal’s abuse deterrent technology in the US market. He was a frequent presenter at conferences and workshops on subjects of abuse prevention and deterrence and the application of technology to impede abuse of prescription drugs.

Since 2017 Dr. Kraus has worked with various companies as a consultant. Most recently he held a position as Head of Search&Evaluation at Aquestive Therapeutics, a specialty CNS pharmaceutical company located in Warren, New Jersey. Since April of 2020 Dr. Kraus has relocated back to Germany and is working as consultant and interim manager.

Dr. Kraus holds a PhD in Chemistry from University of Cologne, Germany. He has both German and US citizenship.

Robert Malleck

Rob Malleck

Senior Advisor

Rob has over 26 years’ senior experience in corporate and investment banking, structured and cross-border finance. He spent 25+ years at Citigroup’s corporate and investment banking department where he oversaw a range of transactions, including investment and non-investment grade, fixed income debt, derivatives and all manner of credit-based engagements. Rob has extensive experience arranging facilities in conjunction with U.S. Ex-Im Bank, MARAD Title XI, DFC (OPIC), IFC, MIGA, IDB, CAF, BNDS, Finnvera, SACE Simest and KExim/Ksure.

Rob holds a FINRA – Series 7 (Registered Rep), Series 63 and Series 24 licenses and is a registered representative with our affiliated BA Investments, our affiliated broker dealer.

Rob has over 26 years’ senior experience in corporate and investment banking, structured and cross-border finance. Along side his work at Princeton Capital Advisors, Rob is a Series A investor in the acquisition of Burmester & Vogel, a leading maritime technology platform.

He spent 25+ years at Citigroup’s corporate and investment banking department where he was a Managing Director in Citi’s Global Energy group, acting as senior banker and trusted advisor to a range of leading internationally-focused oil field service providers. Prior to that, Rob headed Citi’s North American maritime franchise where he covered both energy related offshore clients, U.S. Jones Act firms and international shipping companies. He oversaw the origination, structuring and execution of a wide range of transaction types including liability management engagements, investment and non-investment grade, fixed income debt, derivatives and all manner of credit-based engagements. His earliest work at Citi was in the project and structured trade finance group, where he organized large-scale cross-border loans on a limited and non-recourse basis for a range of industrial and energy sponsors. Rob has extensive experience arranging facilities in conjunction with leading export and multi-lateral credit agencies like the U.S. Ex-Im Bank, MARAD Title XI, DFC (OPIC), IFC, MIGA, IDB, CAF, BNDS, Finnvera, SACE Simest and KExim/Ksure. A number of his transaction’s were named debt deals of the year by Euromoney.

Rob holds securities licenses with FINRA – Series 7 (Registered Rep), Series 63 and Series 24, investment banking principal. He was named Business Senior Credit Officer at Citi in 2014.

Mr. Malleck has a Master’s in International Affairs from Columbia University’s School of International and Public Affairs, during which time he received a Fulbright grant to attend the Inter-University Program for Chinese Language Study, an adjunct to his attendance in Columbia’s East Asia Institute.

John Osborn

Senior Advisor

John Osborn, JD/MIPP has been a general counsel and senior corporate affairs executive with Fortune 1000 biopharmaceutical and healthcare companies, an advisor to leading private equity and venture capital firms, and a board member for biomedical device, digital health and speciality pharmaceutical companies. He is a thought leader who has published widely on public policy issues in leading journals and online for Forbes.com, and has held visiting and adjunct academic appointments at Oxford, Princeton and UCLA.

JOHN E. OSBORN has been a life sciences industry executive and board member, lawyer, lecturer, writer and diplomat. He is a senior advisor with the international law firm Hogan Lovells and a venture partner with the medtech venture capital firm BioVentures.

For more than twenty years, John was a senior executive and general counsel with notable life sciences and healthcare companies, including Fortune 1000 company Cephalon, McKesson Specialty Health/US Oncology, Dendreon and Onyx Pharmaceuticals. In these roles he was responsible for directing the legal and corporate affairs functions, including corporate governance, intellectual property, government relations and public policy, corporate communications, investor relations, risk management, internal audit, compliance and quality assurance. In his first in-house position, he was chief counsel for the medical imaging and European business units of the DuPont Merck Pharmaceutical joint venture company. He also has been an executive in residence and an industry advisor with Warburg Pincus, as well as a board member of publicly traded and privately held companies in the specialty pharmaceutical, healthcare IT and biomedical device sectors.

John was nominated by President George W. Bush in 2007, and confirmed by the United States Senate in 2008, to serve as a member of the bipartisan United States Advisory Commission on Public Diplomacy. After working on the presidential campaigns of George H.W. Bush, he served from 1989 to 1992 with the U.S. Department of State under Secretary James A. Baker III. Following law school, he clerked for Senior Circuit Judge Albert V. Bryan of the U.S. 4th Circuit Court of Appeals. Early in his career, he worked on Capitol Hill in the offices of former Congressman Jim Leach (R-Iowa), the late Senator John Heinz (R-Pa.) and the Congressional Budget Office.

John is an affiliate professor at the University of Washington School of Law, Seattle and lectures regularly at the University of Michigan Ross School of Business, Ann Arbor. He has held visiting research appointments at Oxford (socio-legal studies), Princeton (politics) and the University of California, Los Angeles (public health). He also has been a member of the board of governors of the East-West Center in Honolulu, a visiting scholar in East European Studies with the Woodrow Wilson International Center for Scholars, and an Eisenhower Fellow to Northern Ireland. John has been published widely in scholarly journals, in the press, and online at Forbes.com, STAT Health and Xconomy.

John attended the College of William & Mary and is a Phi Beta Kappa graduate of The University of Iowa.  He holds a master’s degree in international public policy from the Johns Hopkins School of Advanced International Studies, completed additional graduate work at the Princeton School of Public and International Affairs, and earned his law degree at the University of Virginia. He has been elected to membership in the Council on Foreign Relations, the American Law Institute, and the Fellows of the American Bar Foundation, and was named by Lawdragon to its 2008 ranking of the 500 Leading Lawyers in America.

Wendy Perrow, MBA

Senior Advisor

Wendy Perrow is a Pharmaceutical and Biotechnology leader. Ms. Perrow previously served as CEO of AsclepiX Therapeutics, Inc. and Alba Therapeutics, Inc., as well as in senior roles at Sigma-Tau Pharmaceuticals and Merck and Co., where she helped launch a range of highly successful products. She is also a member of the Maryland Life Sciences Advisory Board, and advisor to the Maryland Momentum Fund.

Wendy Perrow is a Pharmaceutical and Biotechnology leader.  Ms. Perrow previously served as CEO of AsclepiX Therapeutics, Inc. and Alba Therapeutics, Inc.

Under her leadership, AsclepiX Therapeutics raised $21M via non-dilutive and private investor funding and she brought in the Venture Capital firm Xontogeny / Perceptive as the lead investor for the $35M Series A investment.  She successfully built a team and led development of one of world’s most promising pipelines of novel ophthalmology and oncology peptide therapeutics as CEO of AsclepiX Therapeutics.  Ms. Perrow was awarded Entrepreneur of the Year in Maryland in 2017 and was selected as CEO of the Leadership Excellence Campaign by JP Morgan Chase in 2020.

As CEO of Alba Therapeutics, she completed a licensing agreement with Innovate Biopharmaceuticals, Inc., now 9 Meters Biopharma, Inc.  Alba Therapeutics conducted seven clinical trials in patients with Celiac Disease, completed the largest Phase IIb clinical trial in patients with celiac disease, demonstrated superiority versus the gluten-free diet, created and validated the 1st Celiac Disease Patient Reported Outcome (CeD PRO) with the lead compound Larazotide Acetate.  Larazotide acetate is now in Phase 3 clinical trials.

Ms. Perrow held senior executive positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with Rare and Orphan Diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global markets including Europe, Asia, and Latin America and U.S. At Merck, she held positions in marketing, marketing promotion, international business research analysis, training, and sales. A skilled marketer and business leader, she has led U.S. and Global launches/initiatives for Zocor®, Vasotec®, Varivax®, Cozaar® and Hyzaar®.  Ms. Perrow began her career in a division of Johnson & Johnson.

Wendy received her MBA in International finance and marketing from The Fuqua School of Business at Duke University and received her bachelor’s degree from Eastern Illinois University.  She is a member of the Maryland Life Sciences Advisory Board – appointed by Governor Larry Hogan, Advisor to the Maryland Momentum Fund, Maryland TEDCO Review Board, Healthcare Business Women’s Association, and Co-Chair of Executive Women in Bio.

Sharmila Rao

Sharmila Rao

Advisor

Sharmila is an advisor to PCA with over 15 years senior experience in life science consulting, pharmaceutical strategy, finance management and biomedical research.

Sharmila worked as consultant at life science consulting firm Defined Health Inc. (now Cello), and a senior financial analyst at Merck Inc. covering Europe, Middle East and Africa region. She did her postdoctoral fellowship at Memorial Sloan Kettering Cancer center and a senior research fellow at the Wadsworth Center, specializing in drug development and precision oncology research. She has published papers in leading academic publications. She received her MBA from Cornell University and a PhD in biochemistry from the Graduate Center at CUNY.

Our approach and focus are different from most of our peers in a number of ways that are important to clients.
Contact us today to see how we can help your business.

CONTACT US